FOXO4-DRI
Also known as: FOXO4-DRI Peptide, Proxofim
A senolytic peptide that selectively eliminates senescent cells.
Overview
FOXO4-DRI is a modified peptide that disrupts the interaction between FOXO4 and p53 in senescent cells, leading to their selective apoptosis. It represents a targeted approach to clearing accumulated senescent cells.
Mechanism of Action
Senescent cells rely on FOXO4-p53 interaction for survival. FOXO4-DRI peptide competes for p53 binding, releasing p53 to trigger apoptosis specifically in senescent cells while sparing normal cells.
Pharmacokinetics
D-retro-inverso modification enhances stability. Requires multiple doses for senolytic effect. Penetrates tissues including CNS.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research
5 mg/kg
3x per week
3-4 weeks
Based on mouse studies; human dosing unknown
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Selective elimination of senescent cells in mice
- 2Restored fitness and fur density in aged mice
- 3Improved kidney function in aged animals
- 4Did not affect non-senescent cells
Side Effects & Contraindications
Reported Side Effects
- Unknown in humans
Contraindications
- Compromised wound healing
- Pregnancy
Safety Considerations
Limited human data. Theoretical concerns about eliminating beneficial senescent cells. Expensive to synthesize.
Storage Requirements
Store lyophilized at -20C
Scientific References
- 1